|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: ZNF410 |
Gene summary for ZNF410 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | ZNF410 | Gene ID | 57862 |
| Gene name | zinc finger protein 410 | |
| Gene Alias | APA-1 | |
| Cytomap | 14q24.3 | |
| Gene Type | protein-coding | GO ID | GO:0006139 | UniProtAcc | Q86VK4 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 57862 | ZNF410 | LZE4T | Human | Esophagus | ESCC | 5.47e-18 | 4.28e-01 | 0.0811 |
| 57862 | ZNF410 | LZE5T | Human | Esophagus | ESCC | 1.40e-06 | 3.32e-01 | 0.0514 |
| 57862 | ZNF410 | LZE7T | Human | Esophagus | ESCC | 4.33e-11 | 3.31e-01 | 0.0667 |
| 57862 | ZNF410 | LZE8T | Human | Esophagus | ESCC | 5.66e-07 | 2.29e-01 | 0.067 |
| 57862 | ZNF410 | LZE20T | Human | Esophagus | ESCC | 2.37e-09 | 2.98e-01 | 0.0662 |
| 57862 | ZNF410 | LZE22D1 | Human | Esophagus | HGIN | 4.30e-07 | 3.05e-01 | 0.0595 |
| 57862 | ZNF410 | LZE22T | Human | Esophagus | ESCC | 3.88e-21 | 9.61e-01 | 0.068 |
| 57862 | ZNF410 | LZE24T | Human | Esophagus | ESCC | 4.28e-25 | 4.69e-01 | 0.0596 |
| 57862 | ZNF410 | LZE22D3 | Human | Esophagus | HGIN | 1.73e-02 | 4.37e-01 | 0.0653 |
| 57862 | ZNF410 | LZE21T | Human | Esophagus | ESCC | 9.73e-05 | 2.73e-01 | 0.0655 |
| 57862 | ZNF410 | LZE6T | Human | Esophagus | ESCC | 9.07e-08 | 2.92e-01 | 0.0845 |
| 57862 | ZNF410 | P1T-E | Human | Esophagus | ESCC | 1.64e-05 | 2.74e-01 | 0.0875 |
| 57862 | ZNF410 | P2T-E | Human | Esophagus | ESCC | 5.30e-21 | 3.51e-01 | 0.1177 |
| 57862 | ZNF410 | P4T-E | Human | Esophagus | ESCC | 3.74e-25 | 4.56e-01 | 0.1323 |
| 57862 | ZNF410 | P5T-E | Human | Esophagus | ESCC | 2.56e-16 | 3.19e-01 | 0.1327 |
| 57862 | ZNF410 | P8T-E | Human | Esophagus | ESCC | 3.02e-26 | 4.80e-01 | 0.0889 |
| 57862 | ZNF410 | P9T-E | Human | Esophagus | ESCC | 1.08e-07 | 2.05e-01 | 0.1131 |
| 57862 | ZNF410 | P10T-E | Human | Esophagus | ESCC | 2.55e-31 | 5.47e-01 | 0.116 |
| 57862 | ZNF410 | P11T-E | Human | Esophagus | ESCC | 4.50e-19 | 6.26e-01 | 0.1426 |
| 57862 | ZNF410 | P12T-E | Human | Esophagus | ESCC | 5.03e-37 | 5.95e-01 | 0.1122 |
| Page: 1 2 3 4 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Lung |  | AAH: Atypical adenomatous hyperplasia |
| AIS: Adenocarcinoma in situ | ||
| IAC: Invasive lung adenocarcinoma | ||
| MIA: Minimally invasive adenocarcinoma |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ZNF410 | PLA | Breast | Healthy | GPRC5A,NPM3,AC092803.2, etc. | 1.05e-01 |  |
| ZNF410 | PLA | Breast | IDC | GPRC5A,NPM3,AC092803.2, etc. | 1.39e-01 |  |
| ZNF410 | CD8TEXP | Breast | IDC | GPRC5A,NPM3,AC092803.2, etc. | 5.14e-02 | |
| ZNF410 | PLA | Breast | Precancer | GPRC5A,NPM3,AC092803.2, etc. | 1.28e-01 |  |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| ZNF410 | SNV | Missense_Mutation | novel | c.8N>T | p.Ser3Leu | p.S3L | Q86VK4 | protein_coding | deleterious_low_confidence(0) | probably_damaging(0.961) | TCGA-AC-A2QI-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | cytoxan | CR |
| ZNF410 | SNV | Missense_Mutation | novel | c.1301N>G | p.Ser434Cys | p.S434C | Q86VK4 | protein_coding | deleterious(0) | possibly_damaging(0.781) | TCGA-C5-A1MH-01 | Cervix | cervical & endocervical cancer | Female | >=65 | III/IV | Chemotherapy | cisplatin | PD |
| ZNF410 | SNV | Missense_Mutation | c.1281N>C | p.Leu427Phe | p.L427F | Q86VK4 | protein_coding | deleterious(0.02) | probably_damaging(0.986) | TCGA-Q1-A73O-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
| ZNF410 | SNV | Missense_Mutation | c.299G>A | p.Gly100Asp | p.G100D | Q86VK4 | protein_coding | tolerated_low_confidence(0.22) | benign(0.036) | TCGA-AA-3663-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD | |
| ZNF410 | SNV | Missense_Mutation | c.566C>T | p.Ala189Val | p.A189V | Q86VK4 | protein_coding | deleterious(0) | probably_damaging(0.98) | TCGA-AA-3833-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| ZNF410 | SNV | Missense_Mutation | c.1025N>A | p.Ser342Asn | p.S342N | Q86VK4 | protein_coding | deleterious(0.03) | probably_damaging(0.983) | TCGA-AA-3971-01 | Colorectum | colon adenocarcinoma | Male | <65 | III/IV | Chemotherapy | folinic | CR | |
| ZNF410 | SNV | Missense_Mutation | c.609N>T | p.Lys203Asn | p.K203N | Q86VK4 | protein_coding | deleterious(0) | probably_damaging(0.985) | TCGA-AA-A00N-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD | |
| ZNF410 | SNV | Missense_Mutation | c.995N>T | p.Gly332Val | p.G332V | Q86VK4 | protein_coding | deleterious(0.03) | probably_damaging(1) | TCGA-D5-6530-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD | |
| ZNF410 | insertion | Frame_Shift_Ins | novel | c.1350_1351insTCTATTT | p.Leu451SerfsTer8 | p.L451Sfs*8 | Q86VK4 | protein_coding | TCGA-AM-5820-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD | ||
| ZNF410 | SNV | Missense_Mutation | novel | c.700A>G | p.Lys234Glu | p.K234E | Q86VK4 | protein_coding | deleterious(0) | benign(0.215) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |